December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Tempest Therapeutics, Inc. - Common Stock (NQ:TPST)

1.020 +0.103 (+11.27%)
Streaming Delayed Price Updated: 10:04 AM EDT, Aug 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Tempest Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
Tempest Reports Second Quarter 2023 Financial Results and Provides Business Update
From Tempest Therapeutics
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
Tempest Announces Publication in Cancer Research Communications Highlighting TPST-1495 Significantly Increased Potency Against Prostaglandin-Driven Tumor Models by Blocking EP2 and EP4 Together
From Tempest Therapeutics
Via GlobeNewswire
News headline image
Analyst Ratings for Tempest Therapeutics ↗
 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Wednesday ↗
  Wednesday saw 59 companies set new 52-week lows. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Tempest to Present at the Jefferies Global Healthcare Conference
From Tempest Therapeutics
Via GlobeNewswire
News headline image
Tempest to Present Phase 1 Monotherapy and Combination Data at ASCO for TPST-1495 in Patients with Advanced Cancers
From Tempest Therapeutics
Via GlobeNewswire
News headline image
Tempest Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Tempest Therapeutics
Via GlobeNewswire
News headline image
Tempest Reports First Quarter 2023 Financial Results and Provides Business Update
From Tempest Therapeutics
Via GlobeNewswire
News headline image
Tempest Therapeutics' TPST-1120 Shines In Early Phase 1b/2 Study: Analysts Get Bullish ↗
Tempest Therapeutics Inc (NASDAQ: TPST) announced  
Via Benzinga
News headline image
Dow Surges Over 200 Points; Exxon Mobil Earnings Beat Views ↗
U.S. stocks traded higher midway through trading, with the Dow Jones gaining over 200 points on Friday. The Dow traded up 0.63% to 34,039.34 while the NASDAQ rose 0.35% to 12,184.79. The S&P 500, also... 
Via Benzinga
News headline image
Tempest Therapeutics (NASDAQ: TPST) Reports Strong Early Results From Phase 1b/2 Study of TPST-1120 in Hepatocellular Carcinoma
Tempest Therapeutics, Inc. (NASDAQ: TPST) is engaged as a clinical-stage oncology company, which is focused on the research and development 
Via Spotlight Growth
News headline image
Why First Republic Bank Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗
Gainers Magic Empire Global Limited (NASDAQ: MEGL) shares jumped 268% to $3.42 after dropping around 8% on Thursday. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Tempest Announces Positive Early Results from Global Randomized Phase 1b/2 Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma
From Tempest Therapeutics
Via GlobeNewswire
News headline image
Tempest to Report Early Results from Global Randomized Phase 1b/2 Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma
Webcast Conference Call Friday, April 28, 2023, at 8:30 a.m. ET 
From Tempest Therapeutics
Via GlobeNewswire
News headline image
Tempest Announces TPST-1495 Poster Presentation at the 2023 ASCO Annual Meeting
From Tempest Therapeutics
Via GlobeNewswire
News headline image
Why Travelers Companies Shares Are Trading Higher By Over 5%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗
Gainers China Jo-Jo Drugstores, Inc. (NASDAQ: CJJD) gained 85.2% to $1.25 after the company announced the termination of its previously proposed registered direct offering. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
Tempest Announces New Translational and Preclinical Data Presented at the 2023 AACR Annual Meeting
From Tempest Therapeutics
Via GlobeNewswire
News headline image
Why Glory Star New Media Group Shares Are Trading Higher By 122%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
Gainers Glory Star New Media Group Holdings Limited (NASDAQ: GSMG) shares jumped 122% to $1.07 after the company announced the signing of a $60 million strategic investment with two institutional... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
Why Kodiak Sciences Shares Are Trading Higher By 18%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗
Gainers LogicMark, Inc. (NASDAQ: LGMK) shares jumped 76.1% to $0.2466 after the company announced financial results for the year ended 2022. The company reported FY22 revenue of $11.9 million. 
Via Benzinga
News headline image
Tempest Reports Year End 2022 Financial Results and Provides Business Update
From Tempest Therapeutics
Via GlobeNewswire
News headline image
Tempest to Present Biomarker Data for TPST-1120 at the Society for Immunotherapy of Cancer (SITC) 2023 Spring Scientific Meeting
From Tempest Therapeutics
Via GlobeNewswire
News headline image
Tempest to Present New Translational and Preclinical Data at the 2023 AACR Annual Meeting
From Tempest Therapeutics
Via GlobeNewswire
News headline image
Why RAPT Therapeutics Shares Are Trading Lower By Over 30%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
Gainers Ainos, Inc. (NASDAQ: AIMD) shares jumped 69.3% to $1.27 after the company announced it signed a Memorandum of Understanding with Merdury Biopharmaceutical to jointly explore and develop a... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.